Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle of the week is already here, which means there is much to do. No doubt, you can relate on some level. So please join us as we grab a cup of stimulation — remember, no prescription is required — and tackle the phone calls and Zoom meetings and deadlines that are piling up. Meanwhile, here is the latest grab of items of interest to help you along. Hope your day is productive and safe. And do stay in touch. …
President Trump spoke on Tuesday as if his campaign depends on a Covid-19 vaccine. Specifically, a vaccine approval by Election Day, STAT observes. Throughout a turbulent, disorganized, and hostile debate, Trump highlighted his government’s efforts on vaccine development, pledging, dubiously, that the country is “weeks away from a vaccine” and contradicting high-level officials within his own government who have suggested it will be months, at least, before a vaccine is available.
New data from Regeneron Pharmaceuticals (REGN) seem likely to add to the excitement about drugs called monoclonal antibodies as treatments for Covid-19, but experts caution more data will be needed to know how potentially beneficial the medicines are, STAT explains. A high dose of its antibody cocktail, REGN-COV2, led levels of the virus to decrease more quickly in infected, non-hospitalized patients, potentially indicating the treatment may help them get better.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect